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2Tuberculosis (TB) was ﬁrst identiﬁed by Robert Koch in 1882.
adly, even after a century since Koch’s breakthrough discovery, TB
ontinues to kill over 1.5 million people every year [1] . Every year,
early 9.5 million new cases of TB occur worldwide [1] . Of these,
early 3 million TB patients are considered ‘missing’—they are ei-
her not diagnosed, or not reported to TB control programs [1] . 
In 2014, according to the World Health Organization (WHO),
bout 80% of reported TB cases occurred in 22 countries [1] . The
ix countries that stand out as having the largest number of inci-
ent cases in 2014 were India, Indonesia, Nigeria, Pakistan, People’s
epublic of China, and South Africa [1] . 
In 2014, India alone accounted for nearly 25% of the 9.5 mil-
ion global TB cases; India also accounted for a third of the three
illion missing TB cases [1] . TB is a major cause of deaths in In-
ia, and the emergence of severe forms of drug-resistant TB in
rban areas such as Mumbai is another indication that the TB
roblem is not under control [2] . There are several likely reasons
or India’s persistent TB problem, including social determinants
nd co-morbidities that fuel the TB epidemic, under-investment
y the government, weak programme implementation, subopti-
al quality of care in the private sector, and insuﬃcient advocacy
round TB [3] . 
In contrast to India, the TB epidemic in sub-Saharan Africa is
haracterized by high prevalence of HIV and TB co-infection, and a
ajor problem with multidrug-resistant TB (MDR-TB) in countries
uch as South Africa, which also has the largest number of people
iving with HIV. The combination of HIV and TB poses immense
hallenges for TB control in Africa, as both infections work syner-
istically to cause morbidity and mortality [4] . 
To curb the TB epidemic, we will need to reach the missing TB
atients, diagnose TB without long delays, and make sure they take
he full course of anti-tuberculosis therapy. Only then will they
top transmitting the infection to those around them. We also need
o make sure all TB-HIV co-infected patients have access to anti-
etroviral therapy, and interventions of proven value, such as pre-
entive therapy for latent TB infection. 
Reaching all the missing patients and ensuring appropriate TB
reatment will require doctors and TB control programs to adopt
nd scale-up the best tools we have today, and modernize TB care.
ompared to the situation even a decade ago, we have witnessed
ig changes in the TB technology landscape. We now have tools
uch as Xpert MTB/RIF that can rapidly and accurately detect TB,
ncluding drug-resistance [5] . With more laboratories offering suchttp://dx.doi.org/10.1016/j.jctube.2016.02.001 
405-5794/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article uapid tests, there has been a substantial increase in the number of
ultidrug-resistant (MDR) cases detected [6] . 
On the new drug front, bedaquiline and delamanid are already
n the market in some countries. In addition, trials are underway
o evaluate the eﬃcacy of a new TB regimens such as PaMZ (which
ontains pretomanid, moxiﬂoxacin, and pyrazinamide), and BPaZ
bedaquiline, pretomanid, and pyrazinamide). If these trials suc-
eed, then TB patients might get new, shorter treatments within
he next 5 years. 
While the product landscape is looking promising, what is wor-
isome is the implementation gap. A recent report called "Out of
tep” by MSF and Stop TB Partnership surveyed 24 high TB burden
ountries, to see how already existing TB policies and interventions
re being implemented [7] . This survey found major implementa-
ion gaps. For example, only eight countries surveyed had revised
heir national policies to include Xpert MTB/RIF as the initial di-
gnostic test for all adults and children with presumptive TB, re-
lacing smear microscopy. Six countries still recommended inter-
ittent treatment for drug-sensitive TB. Even proven interventions
uch as ﬁxed dose combinations are not routinely used in all coun-
ries. 
Other studies have shown similar implementation failures. For
xample, even though South Africa has scaled-up rapid molecular
esting, there are data showing long gaps between sample collec-
ion and initiation of TB treatment [8] . Empirical TB management
s widespread, even with Xpert roll-out, and health system weak-
esses have blunted the impact of new diagnostics [9] . In South
frica, only about half of all patients with TB and HIV are on anti-
etroviral therapy, and only about 50% of TB patients with MDR are
n second-line therapy. These gaps in the TB/HIV treatment cas-
ade underscore the need for better program management. 
In India, an average TB patient is diagnosed after a delay of
early 2 months, and after seeing three providers [10] . At the pri-
ary care level, TB testing is rare, even among those with clas-
ic TB symptoms, and most patients are managed with repeated
ycles of empirical broad-spectrum antibiotic therapies. Indian
tudies also show major gaps in TB knowledge and self-reported
ractices of providers, suggesting poor adherence to established
tandards in the private sector [11] . A recent study, using simu-
ated patients, conﬁrmed the overall low quality of TB care in the
rivate sector, and revealed a substantial gap between what doc-
ors know and what they actually do in their practice [12] . While
DR-TB treatment services have expanded, only 24,073 of thender the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). 
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 estimated 50,0 0 0–74,0 0 0 MDR-TB cases were initiated on treat-
ment in 2014 [1] . 
These issues reinforce the message that technologies alone are
never enough. Good technologies and interventions need to be ef-
fectively implemented for impact to be seen. High-burden coun-
tries will need to improve the eﬃciency of its healthcare delivery
system, and ensure better uptake of new technologies, and achieve
greater linkages across the TB and HIV care continuum. While we
wait for next-generation technologies, national TB programs must
scale-up the current best diagnostics. While we wait for shorter
drug regimens, doctors and programs can improve the effective-
ness of existing treatments by improving treatment adherence. For
example, we can and must harness the enormous potential offered
by mobile phones to electronically monitor adherence to medica-
tions. There are other innovations such as smart pill boxes and
ﬁxed-dose combination drugs that can be better exploited. 
In summary, it is time for doctors, hospitals, and healthcare
programs to embrace and scale-up new TB technologies and ad-
dress implementation gaps to make sure TB patients get the best
care that they deserve. This is absolutely fundamental to reach the
goals set out in the End TB Strategy. 
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